Navigation Links
ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
Date:11/1/2007

RANCHO CORDOVA, Calif., Nov. 1 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that harvest, process, store, and administer therapeutic doses of adult stem cells for treatment of disease and injury, announced today it will report financial results for the fiscal first quarter ended September 30, 2007, on Thursday, November 8, 2007.

Company's Conference Call and Webcast

Management will host a conference call Thursday, November 8, 2007 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal first quarter financial results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Dr. William Osgood, Chief Executive Officer and Matthew Plavan, Chief Financial Officer will host the call to discuss the first quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.

To listen to the audio web cast of the call during or after the event, please visit: http://www.thermogenesis.com/investor_relations/index.asp.

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 877-344-7529 within the U.S. or 412-317-0088 outside the U.S. and entering the following account number when prompted '385107'.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by

cord blood stem cell banks in more than 25 countries for

cryopreserving and archiving cord blood stem cell units for

transplant. GE Healthcare is the non-exclusive global distribution

partner for the BioArchive System.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary, automated

device and companion sterile blood processing disposable for

harvesting stem cells from cord blood in a closed system. GE

Healthcare is the exclusive global distribution partner for the AXP

AutoXpress Platform.

-- The CryoSeal(R) FS System, an automated device and companion sterile

blood processing disposable, is used to prepare fibrin sealants from

plasma in about an hour. We received FDA approval to market the

CryoSeal FS System in liver resection surgeries in July 2007. The

CryoSeal FS System has received the CE-Mark. From a marketing

perspective, the CE Mark is the European equivalent to an FDA

approval, in that it allows sales of the product throughout the

European community. Asahi Medical is the exclusive distributor for the

CryoSeal System in Japan and the Company markets through independent

distributors in Europe and South America.

-- The Thrombin Processing DeviceTM (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

Biologics, Medtronic, Inc. and independent distributors.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Matthew T. Plavan

+1-916-858-5100, or

Ryan Rauch

+1-760-586-8699


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Metavante Corp. will continue M&A activity
2. Lucigen Corp. enters global licensing agreement
3. CIO Leadership Series: Jane Durment, Marcus Corp.
4. Brady Corp. acquires Korean counterpart
5. Brady Corp. raises $137 million in public offering
6. Symphony Corp. and CareEvolution to partner
7. RedPrairie Corp. introduces new supply chain software
8. California investors acquire RedPrairie Corp.
9. Symphony Corp. moving into Fitchburg Technology Campus
10. Local group building Dane County economic development corp.
11. M & Is Metavante completes Brasfield Corp. acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, ... become a Wonderware Certified System Integrator Partner. Huffman Engineering is the only ... , “The System Integrator Partner certification gives customers confidence that our engineers are ...
(Date:12/7/2016)... /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company ... products for the treatment of cancer, today announced ... Development Program with Cytovance Biologics ( Oklahoma ... antibody product. Supported by recent positive interim clinical ... ovarian cancer patients, OncoQuest has engaged Cytovance to ...
(Date:12/7/2016)... Ontario , Dec. 7, 2016  Nordion, ... with General Atomics (GA), welcome today,s award by ... Nuclear Security Administration (NNSA) of the Phase II ... project with Nordion and the University of Missouri ... II funding will support the establishment of a ...
(Date:12/7/2016)... , December 8, 2016 The report "Acrylic Processing Aid Market by ... Packaging, Automotive, Consumer Goods) - Global Forecast to 2026", published by MarketsandMarkets, the ... reach USD 1,173.6 Million by 2026, registering an of CAGR of 6.2% between ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016   Veridium , a leader in ... new CEO James Stickland . Stickland, a ... experience, has served in senior executive roles for ... in expanding a pipeline of venture capital and ... recently served as managing director of U.K.-based fintech ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
Breaking Biology News(10 mins):